Belpointe Asset Management LLC Has $4.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Belpointe Asset Management LLC boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 42.6% in the third quarter, HoldingsChannel reports. The firm owned 103,248 shares of the biopharmaceutical company’s stock after purchasing an additional 30,833 shares during the quarter. Belpointe Asset Management LLC’s holdings in Bristol Myers Squibb were worth $4,657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of BMY. Trifecta Capital Advisors LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $25,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the period. REAP Financial Group LLC grew its position in shares of Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 428 shares during the last quarter. Finally, DHJJ Financial Advisors Ltd. increased its stake in shares of Bristol Myers Squibb by 51.9% during the second quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 267 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. HSBC restated a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Citigroup restated a “neutral” rating and issued a $53.00 price target (up from $45.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 7th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Finally, Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $56.86.

Bristol Myers Squibb Trading Up 0.0%

Shares of Bristol Myers Squibb stock opened at $54.67 on Tuesday. The firm’s 50 day moving average is $52.72 and its 200 day moving average is $48.45. The firm has a market capitalization of $111.29 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date of this dividend is Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 85.14%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.